Significantly lower risk is seen for hospitalization and recovery. 3 studies from 2 independent teams in 2 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 41% [-13‑69%] lower risk, without reaching statistical significance. Currently all studies are RCTs.
Currently there is limited data, with only 410 patients and only 23 control events for the most serious outcome in trials to date. Studies to date are from only 2 different groups.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Propolis currently has no early treatment studies. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Jan 2025, preprint, 1 author.
